Home » Newsletters » BioWorld Science

BioWorld Science

April 7, 2006

View Archived Issues

Oregovomab under investigation in epithelial ovarian cancer

Inolimomab treatment in pediatric graft-versus-host disease reviewed

Nabi licenses ATG-Fresenius S for U.S. and Canada

Valera acquires rights to Valstar

Vaxon-Biotech and Institut Pasteur collaborate on cancer immunotherapy

Enrollment open in first pivotal study of cangrelor

Scynexis and Xsira design new selective GRK-2 inhibitors

Potent FXR antagonists from Amgen

Amazon Biotech preparing HIV studies for AMZ-0026

Bionomics receives Australian grant to advance vascular disruption agent

Innate Pharma and Novo Nordisk partner on drugs targeting natural killer cells

Phase III study of Efaproxyn cleared to continue

CytRx completes enrollment in phase IIa study of arimoclomol for ALS

QLT and Retinagenix sign agreement in retinal diseases

Cordis to establish global cardiac and vascular institute

OncoMethylome to participate in phase III study of temozolomide

Amorfix obtains rights to additional novel SOD1 targets

New phase II study evaluates OT-551 in geographic atrophy

Enrollment completed in phase I study of Provacel in heart attack patients

Viral Therapeutics changes name to Vybion

Duramed withdraws Lo Seasonale NDA

Roche presents novel and selective GlyT1 inhibitor as a candidate for schizophrenia

Unibioscreen develops novel lactosylated steroids with antimigratory activity against cancer cells

Wyeth selects potent Src kinase inhibitor from new series

PARP inhibitor simultaneously enhances antitumor activity and reduces neuropathy of cisplatin

Recent patents cover therapeutic agents for neurological disorders

New analgesic agents reported in recent patent literature

Novel tachykinin NK1 antagonists prepared and tested by Takeda

Novel potent fibrate analogues synthesized at Dr. Reddy's

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
HX-16108 holds promise for treating inflammatory skin diseases
BioWorld Science
Atopic dermatitis (AD) is an inflammatory skin disease accompanied by pruritus, for which IL-13 and IL-31 are clinically validated targets. Earendil Labs Inc. has...